CUVs announcement today is fantastic and goes to show what Australian biotechs are capable of. What a huge value added to the market cap. I don't believe Dimerix is planning on getting as far as CUV on its own, but now, if it wasn't already, the spotlight will be on Aussie biotechs for licencing and acquisition opportunities. Amazing timing for Dimerix to be in phase 2 at the mo.
Ann: Receipt of R&D Tax Incentive, page-10
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |